Hermann Russ, M.D. Ph.D.

Managing Director, Founder, Senior Consultant

 

Dr. Russ is visionary pharma leader, an innovative scientist, and a physician dedicated to bring new treatments to patients in need. By training ne is a board-certified clinical neurologist, a board-certified experimental pharmacologist and a pharmacist. He founded Sirius Scientific Consulting AG in December 2018.  

Dr. Russ holds a Ph.D. in neuro- and biochemistry from the University of Wurzburg, Germany. During his academic career (until 1999) at the Universities of Wurzburg, Regensburg and Giessen he had different positions and functions including consultant of clinical neurology and professor of pharmacology. His scientific focus is on neurodegenerative diseases, including Alzheimer's, Parkinson`s, and degenerative retina diseases. He is (co)inventor of around 25 patents and (co)authors of around 50 peer-reviewed scientific publications.

Dr. Russ has 20 years of Pharma industry experience. He is consulting Galimedix Inc. (www.galimedix.com) in the function as Chief Scientific Officer, Co-Founder and Member of the Board of Directors since 2018. Prior to that he was Vice President of Neuroscience Project Leadership in Specialty R&D of Teva Pharmaceuticals International GmbH (TPIG) Switzerland. His responsibilities included the strategic leadership and management of "project champions" of all global cross-functional drug development programs in the area CNS and pain throughout all phases. He also served on the Swiss Board of TPIG as Managing Officer. Before that he worked for 8 years at Merz Pharma as Head of Global R&D CNS leading a R&D organization in the CNS indication area, spanning from early discovery to clinical development and regulatory submission. That included management of five R&D departments. From 1999 to 2007 Dr. Russ was with Merck KGaA as Head of the Medical Center of Excellence CNS (last position).

Dr. Russ was closely involved the approval of 8 different drugs (6 different molecules), including small molecules, antibodies, other biologicals and medical devices. His regulatory experience is based on many meetings with the FDA, the EMA, and different local EU authorities.